About: COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies
Creator	Med, M Lacourse, Sylvia Maleche-Obimbo, Elizabeth Nachman, Sharon Conway, James Garcia-Prats, Anthony Hesseling, Anneke Radtke, Kendra Salazar-Austin, Nicole Savic, Rada
source	Medline; PMC
abstract	Clinical trials of pharmacologic treatments of coronavirus disease 2019 (COVID-19) are being rapidly designed and implemented in adults. Children are often not considered during development of novel treatments for infectious diseases until very late. Although children appear to have a lower risk compared to adults of severe COVID-19 disease, a substantial number of children globally will benefit from pharmacologic treatments. It will be reasonable to extrapolate efficacy of most treatments from adult trials to children. Pediatric trials should focus on characterizing a treatment’s pharmacokinetics, optimal dose and safety, across the age spectrum. These trials should use an adaptive design to efficiently add or remove arms in what will be a rapidly evolving treatment landscape, and should involve a large number of sites across the globe in a collaborative effort to facilitate efficient implementation. All stakeholders must commit to equitable access to any effective, safe treatment for children everywhere.
has issue date	2020-06-29(xsd:dateTime)
bibo:doi	10.1093/cid/ciaa885
bibo:pmid	32594142
has license	no-cc
sha1sum (hex)	1fd85d5a9b47beac4fd9931694d5c9ee2d4ec111
schema:url	https://doi.org/10.1093/cid/ciaa885
resource representing a document's title	COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies
has PubMed Central identifier	PMC7337679
has PubMed identifier	32594142
schema:publication	Clin Infect Dis
resource representing a document's body	covid:1fd85d5a9b47beac4fd9931694d5c9ee2d4ec111#body_text
is schema:about of	named entity 'China' named entity 'clinical practice' named entity 'drug metabolism' named entity 'respiratory failure' named entity 'pediatric' named entity 'treatment of children' named entity 'COVID-19' named entity 'Pharmacokinetic' named entity 'gastrointestinal function' named entity 'PK/PD' named entity 'Critical illness' named entity 'evidence-based' named entity 'influenza' named entity 'tocilizumab' named entity 'PICU' named entity 'health systems' named entity 'COVID' named entity 'global pandemic' named entity 'virus' named entity 'passive immunity' named entity 'body water' named entity 'pediatric' named entity 'COVID-19' named entity 'ribavirin' named entity 'supportive care' named entity 'COVID-19' named entity 'cyanosis' named entity 'COVID' named entity 'safety profile' named entity 'hydroxychloroquine' named entity 'lopinavir/ritonavir' named entity 'pediatric' named entity 'pediatric' named entity 'tuberculosis' named entity 'pharmacologic treatments' named entity 'intensive care' named entity 'pediatric' named entity 'body composition' named entity 'post-exposure' named entity 'remdesivir' named entity 'dyspnea' named entity 'pharmacologic treatments' named entity 'NICHD' named entity 'phase III' named entity 'breastmilk' named entity 'pediatric' named entity 'breastmilk' named entity 'U.S.' named entity 'malnutrition' named entity 'pharmacologic treatment' named entity 'intensive care' named entity 'young children' named entity 'immunosuppressed' named entity 'Chinese Centers for Disease Control' named entity 'adverse effects' named entity 'ICU' named entity 'mechanical ventilation' named entity 'pharmacokinetic' named entity 'medical conditions' named entity 'COVID' named entity 'COVID' named entity 'intensive care' named entity 'COVID-19' named entity 'toxicity' named entity 'circulatory support' named entity 'supportive care' named entity 'sample size' named entity 'renal function' named entity 'risks and benefits' named entity 'pediatric' named entity 'COVID' named entity 'cytokine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software